Log inStart free trialBook a demo
Book a demoLog inStart free trial
Media Database
>
Carol L. DiBerardino

Carol L. DiBerardino

Journalist at Healio

Contact this person
Email address
c*****@*******.comGet email address
Influence score
49
Phone
(XXX) XXX-XXXX Get mobile number
Location
United States
Languages
  • English
Covering topics
  • Health & Medicine

View more media outlets and journalists by signing up to Prowly

View latest data and reach out all from one place
Sign up for free

Recent Articles

healio.com

Buntanetap linked to improved cognition, tau reduction in phase 2/3 study - Healio

In a phase 2/3 clinical trial, treatment with buntanetap was linked to cognitive gains as well as tau reduction at 12 weeks in those exhibiting mild to moderate symptoms of Alzheimer’s disease, according to the drug’s manufacturer.In a press release, Annovis Bio stated that the United States-based study — which was reviewed by the Data and Safety Monitoring Board in October 2023
6 months ago
healio.com

Patient dosing continues in clinical trial of novel gene therapy fo...

A European clinical stage biotech company announced dosing of the first patient in cohort 2 of its ongoing phase 1/2 GATEWAY clinical trial of lead candidate VTX-801 to treat Wilson’s disease. According to a release from Vivet Therapeutics, GATEWAY is a nonrandomized, open-label study conducted across several clinical sites in the United States, United Kingdom, Germany and Denmark. The
9 months ago
healio.com

FDA grants rare pediatric disease designation to alpha kinase inhib...

The FDA has granted rare pediatric disease designation to an alpha-kinase 1 inhibitor to treat patients with retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache, or ROSAH, syndrome.According to a press release from developer Drug Farm, DF-003 is currently being evaluated in a phase 1 clinical trial assessing safety and pharmacokinetics in healthy volunteers.
11 months ago
healio.com

FDA approves Hyqvia for chronic inflammatory demyelinating polyneur...

The FDA has approved Takeda Pharmaceutical’s Hyqvia, coformulated with Halozyme’s Enhanze drug delivery technology, to treat chronic inflammatory demyelinating polyneuropathy in adults.According to a Takeda press release, Hyqvia is the only currently available FDA-approved combination of immunoglobulin (IG) and hyaluronidase for adults with chronic inflammatory demyelinating polyneuropathy
11 months ago
healio.com

FDA approves Ingrezza for chorea associated with Huntington's disea...

The FDA has approved once-daily Ingrezza capsules for adults with chorea associated with Huntington’s disease. According to a release from Neurocrine Biosciences Inc., the selective vesicular monoamine transporter 2 inhibitor Ingrezza (valbenazine, Neurocrine) can be adjusted by a patient’s health care provider based on response and tolerability, with no complex titration.
over 1 year ago
healio.com

Blood test boosts diagnostic accuracy for Alzheimer's by calculatin...

C2N Diagnostics released the PrecivityAD2 blood test, which uses positron emission tomography scans and cerebrospinal fluid tests to assist in accurate diagnosis for those presenting with signs or symptoms of Alzheimer’s disease.According to a company release, in a clinical validation study involving two independent cohorts of 583 patients with cognitive impairment using amyloid positron
over 1 year ago
healio.com

Inspire Medical Systems receives expanded indication for sleep ... ...

The FDA has approved an expanded indication for a proprietary neurostimulation technology to treat those with severe obstructive sleep apnea. According to a release from Inspire Medical Systems Inc, the regulatory body’s approval includes an increase on the upper limit of the therapeutic’s Apnea Hypopnea Index (AHI) to 100 events per hour from 65, as well as raising the BMI label
over 1 year ago
healio.com

Women notably underrepresented in clinical trial leadership - Healio

Women appeared significantly underrepresented as first authors of thousands of randomized controlled trials compared with men, according to study results published in Contemporary Clinical Trials.
almost 2 years ago
healio.com

V Foundation unveils grant program to increase representation of .....

The V Foundation announced a multimillion dollar inaugural program to increase representation of women in cancer research.
almost 2 years ago
healio.com

Hooked on ID with David Boulware, MD, MPH

Infectious Disease News | I grew up in a household surrounded by medicine and the medical needs of my sister. It was an environment I had become accustomed to and later became the focal point of my studies.While performing a research study on long-distance backpackers as a medical student, I was mos…
about 2 years ago
healio.com

NIH awards UCLA $10M to study brain's cellular infrastructure - Healio

The NIH has awarded nearly $10 million to two scientists at UCLA’s David Geffen School of Medicine for research projects that aim to shed light on the development of the brain’s cellular infrastructure as well as brain disorders. Chongyuan Luo, PhD, BSc, assistant professor of human genetics, will receive $5.3 million over 5 years to systematically map the gene regulatory
over 2 years ago